ID

15369

Description

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group; ODM derived from: https://clinicaltrials.gov/show/NCT01511185

Lien

https://clinicaltrials.gov/show/NCT01511185

Mots-clés

  1. 28/05/2016 28/05/2016 -
  2. 20/09/2021 20/09/2021 -
Téléchargé le

28 mai 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Diabetes NCT01511185

Eligibility Diabetes NCT01511185

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01511185
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on oad monotherapy for at least 3 months
Description

type 2 diabetes

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C2585997
UMLS CUI [2,1]
C0011860
UMLS CUI [2,2]
C0935929
UMLS CUI [2,3]
C0442027
body mass index (bmi): 24-35 kg/m^2 inclusive
Description

bmi

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with type 2 diabetes
Description

type 2 diabetes

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
receipt of any investigational drug within three months prior to this trial
Description

investigational drug

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
recurrent severe hypoglycemia as judged by the investigator
Description

hypoglycemia

Type de données

boolean

Alias
UMLS CUI [1]
C0020615
cardiac disease
Description

cardiac disease

Type de données

boolean

Alias
UMLS CUI [1]
C0018799
use of any drug (except an oad (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
Description

drug affecting glucose level

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0202042
haemoglobin maximum 10 g/l
Description

haemoglobin

Type de données

boolean

Alias
UMLS CUI [1]
C0518015
hba1c above 12%
Description

hba1c

Type de données

boolean

Alias
UMLS CUI [1]
C0019018
loss of more than 400 ml blood during the 3 months prior to trial start
Description

bleeding

Type de données

boolean

Alias
UMLS CUI [1]
C0019080
healthy subjects
Description

healthy subject

Type de données

boolean

Alias
UMLS CUI [1]
C1708335
clinically relevant cardiac disease or any clinically significant abnormal ecg (electrocardiogram)
Description

cardiac disease | ecg abnormality

Type de données

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C1832603
hba1c at least 6%
Description

hba1c

Type de données

boolean

Alias
UMLS CUI [1]
C0019018

Similar models

Eligibility Diabetes NCT01511185

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01511185
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
type 2 diabetes
Item
diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on oad monotherapy for at least 3 months
boolean
C0011860 (UMLS CUI [1,1])
C2585997 (UMLS CUI [1,2])
C0011860 (UMLS CUI [2,1])
C0935929 (UMLS CUI [2,2])
C0442027 (UMLS CUI [2,3])
bmi
Item
body mass index (bmi): 24-35 kg/m^2 inclusive
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
type 2 diabetes
Item
subjects with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
investigational drug
Item
receipt of any investigational drug within three months prior to this trial
boolean
C0013230 (UMLS CUI [1])
hypoglycemia
Item
recurrent severe hypoglycemia as judged by the investigator
boolean
C0020615 (UMLS CUI [1])
cardiac disease
Item
cardiac disease
boolean
C0018799 (UMLS CUI [1])
drug affecting glucose level
Item
use of any drug (except an oad (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
boolean
C0013227 (UMLS CUI [1,1])
C0202042 (UMLS CUI [1,2])
haemoglobin
Item
haemoglobin maximum 10 g/l
boolean
C0518015 (UMLS CUI [1])
hba1c
Item
hba1c above 12%
boolean
C0019018 (UMLS CUI [1])
bleeding
Item
loss of more than 400 ml blood during the 3 months prior to trial start
boolean
C0019080 (UMLS CUI [1])
healthy subject
Item
healthy subjects
boolean
C1708335 (UMLS CUI [1])
cardiac disease | ecg abnormality
Item
clinically relevant cardiac disease or any clinically significant abnormal ecg (electrocardiogram)
boolean
C0018799 (UMLS CUI [1])
C1832603 (UMLS CUI [2])
hba1c
Item
hba1c at least 6%
boolean
C0019018 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial